http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2342044-T3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24aca9ded2638ea793d05360dde7a4a0
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D201-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B61-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D201-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D223-10
filingDate 2001-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_719b9499e69b3427d8cc79d865715645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8cdfb7e4ef003b5d84ec1572ffded32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75ca90a332139e6cc749ead4907dde56
publicationDate 2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-2342044-T3
titleOfInvention PROCESS TO PRODUCE EPSILON-CAPROLACTAMA.
abstract A process for producing ε-caprolactam comprising the steps of: (i) pouring raw ε-caprolactam and a first solvent together into a container, in which the crude ε-caprolactam is molten or dissolved in a second solvent comprising a second solvent aliphatic hydrocarbon and, optionally, a second organic solvent having a greater polarity than that of the second aliphatic hydrocarbon and wherein the first solvent comprises a first aliphatic hydrocarbon and, optionally, a first organic solvent having a greater polarity than that of the first aliphatic hydrocarbon, in which the first aliphatic hydrocarbon may be the same or different than the second aliphatic hydrocarbon and in which the first solvent has a temperature lower than the temperature of the crude ε-caprolactam, and mix the ε-caprolactam and the first solvent to obtain a first suspension containing crystallized ε-caprolactam, in which the temperature crystallizes tion is 30 ° C less than the melting point of ε-caprolactam, and (ii) subjecting the suspension to a solid-liquid separation to obtain ε-caprolactam and a first liquid phase.
priorityDate 2000-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526596
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414881286
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449273033
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8114
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11194306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419525574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579231
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419544127
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451679761
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558502
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18373917
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17079
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7768
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8141
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415893423
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416009402
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID236409
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516292
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422133884
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1810164
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424948844
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545610
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452505798
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7967
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489307
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419511072
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14818447
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21477393
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453063016
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6403
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7517
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22494920
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419820529
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7296
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID557502
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10866391

Total number of triples: 59.